Volume | 5,699 |
|
|||||
News | - | ||||||
Day High | 1.1299 | Low High |
|||||
Day Low | 1.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NanoViricides Inc | NNVC | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.10 | 1.10 | 1.1299 | 1.10 | 1.11 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
51 | 5,699 | $ 1.10 | $ 6,292 | - | 1.00 - 2.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
20:00:00 | 100 | $ 1.10 | USD |
NanoViricides Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
12.96M | 11.78M | - | 0 | -8.59M | -0.73 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NanoViricides News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NNVC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.19 | 1.28 | 1.0297 | 1.12 | 17,793 | -0.09 | -7.56% |
1 Month | 1.15 | 1.50 | 1.0297 | 1.28 | 37,396 | -0.05 | -4.35% |
3 Months | 1.14 | 1.50 | 1.0297 | 1.23 | 30,130 | -0.04 | -3.51% |
6 Months | 1.21 | 1.50 | 1.00 | 1.18 | 39,884 | -0.11 | -9.09% |
1 Year | 1.30 | 2.00 | 1.00 | 1.34 | 52,819 | -0.20 | -15.38% |
3 Years | 4.20 | 7.86 | 1.00 | 4.81 | 337,753 | -3.10 | -73.81% |
5 Years | 0.27 | 19.80 | 0.16045 | 7.12 | 688,707 | 0.83 | 307.41% |
NanoViricides Description
Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy. |